E. Ohman J:Or Asset Management Ab Bei Gene, Ltd. Transaction History

E. Ohman J:Or Asset Management Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Apr 05, 2024	SELL	$125.51 - $229.3 $828,366 - $1.51 Million	-6,600 Closed	0 $0
Q2 2022 Apr 05, 2024	SELL	$121.11 - $216.05 $290,664 - $518,520	-2,400 Reduced 26.67%	6,600 $1.07 Billion
Q2 2021 Apr 05, 2024	BUY	$292.75 - $367.01 $234,200 - $293,608	800 Added 9.76%	9,000 $3.09 Billion
Q1 2021 Apr 05, 2024	BUY	$260.64 - $382.12 $208,512 - $305,696	800 Added 10.81%	8,200 $2.85 Billion
Q4 2020 Apr 05, 2024	BUY	$221.31 - $316.61 $1.64 Million - $2.34 Million	7,400 New	7,400 $1.91 Billion

213

45.1M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $25.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.